Aims & Scope
Cardiovascular & Hematological Disorders-Drug Targets aims to cover all the latest and outstanding developments on the medicinal chemistry, pharmacology, molecular biology, genomics and biochemistry of contemporary molecular targets involved in cardiovascular and hematological disorders e.g. disease specific proteins, receptors, enzymes, genes. Each issue of the journal contains a series of in-depth/mini reviews, original research articles, drug clinical trial studies and guest edited thematic issues written by leaders in the field covering a range of current topics on drug targets involved in cardiovascular and hematological disorders. As the discovery, identification, characterization and validation of novel human drug targets for cardiovascular and hematological drug discovery continues to grow; this journal is essential reading for all pharmaceutical scientists involved in drug discovery and development.
BIOBASE, BIOSIS, BIOSIS Previews, BIOSIS Reviews Reports and Meetings, British Library, Cambridge Scientific Abstracts (CSA)/ProQuest, Chemical Abstracts Service/SciFinder, ChemWeb, CNKI Scholar, Dimensions, EBSCO, EMBASE/Excerpta Medica, Genamics JournalSeek, Google Scholar, J-Gate, JournalTOCs, MediaFinder®-Standard Periodical Directory, MEDLINE/PubMed/Index Medicus, Open Abstracts (I4OA), Norwegian Register, PubsHub, QOAM, Scilit, Scopus, Suweco CZ, TOC Premier, and Ulrich's Periodicals Directory.
Quick processing and publication of the submitted papers. The manuscript will be published online within 20 days of final acceptance.
30% discount on the single-issue cost to authors on the purchase of issue(s) in which their article is published.
Multiple issue copies at discounted rates.
Garry X. Shen
Univ. of Manitoba, Canada